146 results
Page 4 of 8
8-K/A
EX-99.4
9hp0e7xvnyk
19 Sep 19
Special Purpose Combined Statements of Revenues and Direct Expenses
9:26pm
8-K/A
EX-99.3
cttc57xfz9u
19 Sep 19
Special Purpose Combined Statements of Revenues and Direct Expenses
9:26pm
8-K/A
EX-99.1
ds2bmqk7r 94eqb
19 Sep 19
Special Purpose Combined Statements of Revenues and Direct Expenses
9:26pm
8-K/A
EX-99.1
pnoa10ug52 38azq
14 Aug 19
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
12:00am
8-K
EX-99.1
7zk7bave62g xfdn
13 Aug 19
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
8:42am
8-K
EX-2.1
lv30n5
19 Jul 19
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
5:03pm
8-K
EX-99.1
zggig9
13 May 19
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
5:21pm
8-K
EX-99.1
ul03jmmsy72ezdr6
19 Mar 19
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
5:17pm
8-K
14miexzr5k
28 Jan 19
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
9:40pm
8-K
EX-99.1
io5n5d3uo8ui4q8o
28 Jan 19
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
9:40pm
8-K
EX-99.2
cbmiyfekhky7
28 Jan 19
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
9:40pm
424B5
83dw i2qgn
28 Jan 19
Prospectus supplement for primary offering
5:29pm
424B5
c3vtb yrbpu87d2
24 Jan 19
Prospectus supplement for primary offering
9:51pm
8-K
EX-99.1
5mr386pj2up
13 Nov 18
Results of Operations and Financial Condition
5:00pm